ImmunoPrecise Declared New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks

ImmunoPrecise Declared New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks

"Global health issues like the COVID-19 pandemic represent significant times for companies like IPA to share our collective expertise and technologies to bring forward safe and efficacious therapies," stated Ali Tehrani, Ph.D., President, and CEO of Zymeworks. "We look forward to continuing our relationship with ImmunoPrecise as they advance multi-specific candidates toward the clinic."

FREMONT, CA: Immunoprecise Antibodies, a leader in full-service, therapeutic antibody discovery and development, declared a research collaboration with Zymeworks, giving ImmunoPrecise access to Zymeworks' Azymetric and EFECT platforms for the further development of its multiple antibody candidates to fight COVID-19.

As a part of the agreement, IPA would transform its previously tested and potent SARS-CoV-2 neutralizing antibodies into bispecific and multi-specific antibodies utilizing the Zymeworks' platforms. These sets of candidates will be thoroughly tested utilizing SARS-CoV-2 spike protein provided by the National Research Council Canada ("NRC"), before pre-clinical manufacturing at the NRC for animal studies. Timelines for the companies' pre-clinical studies examining the success of IPA's Polytope therapies using traditional antibody formats are not impacted by these additional investigations into the formulation.

"Global health issues like the COVID-19 pandemic represent significant times for companies like IPA to share our collective expertise and technologies to bring forward safe and efficacious therapies," stated Ali Tehrani, Ph.D., President and CEO of Zymeworks. "We look forward to continuing our relationship with ImmunoPrecise as they advance multi-specific candidates toward the clinic."

"After the discovery of potently neutralizing antibodies in a combinatorial setting, it was a logical consequence for us to look into clinically-proven, multi-specific antibody platforms," stated Jennifer Bath, Ph.D., President and CEO of ImmunoPrecise Antibodies. "IPA is pleased to collaborate with the Zymeworks team as we work together to treat COVID patients using our extensive, collective expertise."

Jennifer Bath, Ph.D., Chief Executive Officer of ImmunoPrecise, has reviewed and approved the scientific disclosure of this news release.

The company is not making any express or implied claims that its product has the ability to cure, eliminate, or contain COVID-19 (or SARS-CoV-2) at this time.

See Also: Top eClinical Trial Management Consulting/Service Companies